VanEck Pharmaceutical ETF PPH

VanEck Pharmaceutical ETF es un activo que puedes comprar desde Chile con Racional. Conoce a qué se dedica, cómo se compone y qué lo mueve en el mercado, junto con sus datos clave para decidir si calza con tus metas de largo plazo.

Con 9 acciones de PPH (USD 970,53) habrías recibido USD 19,17 en dividendos en los últimos 12 meses.

• Zacks Investment Research 5 oct

  Should You Invest in the VanEck Pharmaceutical ETF (PPH)?

  The VanEck Pharmaceutical ETF (PPH) offers low-cost exposure to the healthcare-pharma sector with a 0.36% expense ratio and $1.01 billion in assets. The fund tracks the MVIS US Listed Pharmaceutical 25 Index and holds major pharmaceutical companies like Eli Lilly, Merck, and Novartis. With a Zacks ETF Rank of 3 (Hold), year-to-date gains of 6.51%, and a medium-risk profile, PPH is presented as a reasonable option for investors seeking diversified pharma exposure, though alternative ETFs like FTXH and IHE are also available.

  

• The Motley Fool 2 oct

  Better Pharmaceuticals ETF: VanEck's PPH vs. Invesco PJP

  VanEck Pharmaceutical ETF (PPH) offers lower costs (0.36% expense ratio) and higher dividend yield (2%), making it better for long-term buy-and-hold investors. Invesco Pharmaceuticals ETF (PJP) delivered stronger 1-year returns (41% vs 31%) with more balanced U.S.-focused holdings, but charges higher fees (0.58%) and offers lower yield (0.9%).

  

• Zacks Investment Research 7 sept

  Here's How Trump's Drug Deals Are Likely to Impact Healthcare ETFs

  President Trump announced expanded Most-Favoured-Nation (MFN) drug pricing agreements with 26 pharmaceutical companies, covering 89% of the branded drug market. The deals include nine additional firms alongside previous agreements with major drugmakers. While lower drug prices may benefit healthcare providers and insurers, the impact on pharmaceutical companies is mixed, with agreements primarily targeting Medicaid and government-sponsored plans rather than employer-sponsored insurance.

  

• The Motley Fool 26 jul

  Is the VanEck Pharmaceutical ETF or State Street Health Care ETF the Better Buy for Your Portfolio?

  The article compares two healthcare ETFs: VanEck Pharmaceutical ETF (PPH), which focuses exclusively on 25 pharmaceutical companies with higher returns but higher costs, and State Street Health Care Select Sector SPDR ETF (XLV), which offers broader diversification across 60 healthcare positions with lower fees. While XLV outperforms over 10 years, PPH delivers superior 3-year and 5-year returns. The article recommends PPH for investors seeking recent performance gains, though XLV offers better cost efficiency and diversification.

  

• The Motley Fool 9 jul

  Vanguard Health Care vs. VanEck Pharmaceutical: How Do These ETFs Stack Up?

  Vanguard Health Care ETF (VHT) offers broad diversification across 429 healthcare holdings with a low 0.09% expense ratio, while VanEck Pharmaceutical ETF (PPH) provides concentrated exposure to 26 drugmakers with higher returns but greater risk. VHT is more cost-effective and diversified, while PPH has delivered superior 5-year returns and higher dividend yield despite concentration risk and a higher 0.36% expense ratio.